Identification of the needs of individuals affected by COVID-19.


Journal

Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676

Informations de publication

Date de publication:
09 May 2024
Historique:
received: 30 05 2023
accepted: 25 04 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: epublish

Résumé

The optimal management of COVID-19 symptoms and their sequelae remains an important area of clinical research. Policy makers have little scientific data regarding the effects on the daily life of affected individuals and the identification of their needs. Such data are needed to inform effective care policy. We studied 639 people with COVID-19 resident in France via an online questionnaire. They reported their symptoms, effects on daily life, and resulting needs, with particular focus on olfaction. The results indicate that a majority of participants viewed their symptoms as disabling, with symptoms affecting their physical and mental health, social and professional lives. 60% of the individuals reported having unmet medical, psychological and socio-professional support needs. Finally, affected individuals were concerned about the risk and invasiveness of possible treatments as shown by a preference for non-invasive intervention over surgery to cure anosmia. It is important that policy makers take these needs into consideration in order to assist affected individuals to regain a normal quality of life. The impact of COVID-19 has been substantial, both on individuals’ health and on society. Information is needed to understand the biological mechanisms underlying the illness and to provide appropriate support for people affected. This study uses data from an online questionnaire of adults diagnosed with COVID-19 to characterize symptoms, understand their impact on peoples’ everyday lives, and determine the support that people need. Our over-arching analysis of symptoms experienced reveals that heart- and skin-related symptoms are linked to chronic illness, and symptoms related to the sense of smell may have a different underlying disease mechanism. Most respondents had a mild initial illness, but their symptoms were long-lasting and had a severe impact. Our findings show that sufferers need different kinds of support in order to regain a normal quality of life.

Sections du résumé

BACKGROUND BACKGROUND
The optimal management of COVID-19 symptoms and their sequelae remains an important area of clinical research. Policy makers have little scientific data regarding the effects on the daily life of affected individuals and the identification of their needs. Such data are needed to inform effective care policy.
METHODS METHODS
We studied 639 people with COVID-19 resident in France via an online questionnaire. They reported their symptoms, effects on daily life, and resulting needs, with particular focus on olfaction.
RESULTS RESULTS
The results indicate that a majority of participants viewed their symptoms as disabling, with symptoms affecting their physical and mental health, social and professional lives. 60% of the individuals reported having unmet medical, psychological and socio-professional support needs. Finally, affected individuals were concerned about the risk and invasiveness of possible treatments as shown by a preference for non-invasive intervention over surgery to cure anosmia.
CONCLUSIONS CONCLUSIONS
It is important that policy makers take these needs into consideration in order to assist affected individuals to regain a normal quality of life.
The impact of COVID-19 has been substantial, both on individuals’ health and on society. Information is needed to understand the biological mechanisms underlying the illness and to provide appropriate support for people affected. This study uses data from an online questionnaire of adults diagnosed with COVID-19 to characterize symptoms, understand their impact on peoples’ everyday lives, and determine the support that people need. Our over-arching analysis of symptoms experienced reveals that heart- and skin-related symptoms are linked to chronic illness, and symptoms related to the sense of smell may have a different underlying disease mechanism. Most respondents had a mild initial illness, but their symptoms were long-lasting and had a severe impact. Our findings show that sufferers need different kinds of support in order to regain a normal quality of life.

Autres résumés

Type: plain-language-summary (eng)
The impact of COVID-19 has been substantial, both on individuals’ health and on society. Information is needed to understand the biological mechanisms underlying the illness and to provide appropriate support for people affected. This study uses data from an online questionnaire of adults diagnosed with COVID-19 to characterize symptoms, understand their impact on peoples’ everyday lives, and determine the support that people need. Our over-arching analysis of symptoms experienced reveals that heart- and skin-related symptoms are linked to chronic illness, and symptoms related to the sense of smell may have a different underlying disease mechanism. Most respondents had a mild initial illness, but their symptoms were long-lasting and had a severe impact. Our findings show that sufferers need different kinds of support in order to regain a normal quality of life.

Identifiants

pubmed: 38724573
doi: 10.1038/s43856-024-00510-1
pii: 10.1038/s43856-024-00510-1
doi:

Types de publication

Journal Article

Langues

eng

Pagination

83

Informations de copyright

© 2024. The Author(s).

Références

WHO COVID-19 Dashboard. World Health Organisation https://covid19.who.int/info (2020).
Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259–264 (2021).
pubmed: 33887749 doi: 10.1038/s41586-021-03553-9
Perlis, R. H. et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA Netw. Open 5, e2238804 (2022).
pubmed: 36301542 pmcid: 9614581 doi: 10.1001/jamanetworkopen.2022.38804
Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626–631 (2021).
pubmed: 33692530 pmcid: 7611399 doi: 10.1038/s41591-021-01292-y
Landry, M. et al. Postacute Sequelae of SARS-CoV-2 in University Setting. Emerg Infect. Dis. 29, 519–527 (2023).
pubmed: 36703253 pmcid: 9973677 doi: 10.3201/eid2903.221522
Tan, B. K. J. et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: Meta-analysis with parametric cure modelling of recovery curves. BMJ https://doi.org/10.1136/bmj-2021-069503 (2022).
Pavli, A., Theodoridou, M. & Maltezou, H. C. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. Arch. Med. Res. 52, 575–581 (2021).
pubmed: 33962805 pmcid: 8093949 doi: 10.1016/j.arcmed.2021.03.010
Sugiyama, A. et al. Long COVID occurrence in COVID-19 survivors. Sci. Rep. 12, 6039 (2022).
pubmed: 35411017 pmcid: 8996498 doi: 10.1038/s41598-022-10051-z
Nasserie, T., Hittle, M. & Goodman, S. N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw. Open 4, e2111417 (2021).
pubmed: 34037731 pmcid: 8155823 doi: 10.1001/jamanetworkopen.2021.11417
Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583–590 (2022).
pubmed: 35132265 pmcid: 8938267 doi: 10.1038/s41591-022-01689-3
Grant, M. C. et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One 15, e0234765 (2020).
pubmed: 32574165 pmcid: 7310678 doi: 10.1371/journal.pone.0234765
Buckley, B. J. R. et al. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur. J. Clin. Invest. 51, e13679 (2021).
pubmed: 34516657 pmcid: 8646627 doi: 10.1111/eci.13679
Xie, Y., Xu, E. & Al-Aly, Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ 376, e068993 (2022).
pubmed: 35172971 doi: 10.1136/bmj-2021-068993
Boscolo-Rizzo, P. et al. Psychophysical assessment of olfactory and gustatory function in post-mild COVID-19 patients: A matched case-control study with 2-year follow-up. Int. Forum Allergy Rhinol. 13, 1864–1875 (2023).
pubmed: 36852674 doi: 10.1002/alr.23148
Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 28, 2406–2415 (2022).
pubmed: 36138154 pmcid: 9671811 doi: 10.1038/s41591-022-02001-z
Melms, J. C. et al. A molecular single-cell lung atlas of lethal COVID-19. Nature 595, 114–119 (2021).
pubmed: 33915568 pmcid: 8814825 doi: 10.1038/s41586-021-03569-1
Delorey, T. M. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595, 107–113 (2021).
pubmed: 33915569 pmcid: 8919505 doi: 10.1038/s41586-021-03570-8
Eberhardt, N. et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat. Cardiovasc. Res. 2, 899–916 (2023).
pubmed: 38076343 pmcid: 10702930 doi: 10.1038/s44161-023-00336-5
Frere, J. J. et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci. Transl Med. 14, eabq3059 (2023).
doi: 10.1126/scitranslmed.abq3059
Faghy, M. A. et al. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom profiles and restore pre-COVID quality of life. Expert Rev. Respir. Med. 16, 595–600 (2022).
pubmed: 35385677 doi: 10.1080/17476348.2022.2063843
Briggs, A. & Vassall, A. Count the cost of disability caused by COVID-19. Nature 593, 502–505 (2021).
pubmed: 34040204 doi: 10.1038/d41586-021-01392-2
Kay, L. M. COVID-19 and olfactory dysfunction: a looming wave of dementia? J. Neurophysiol. 128, 436–444 (2022).
pubmed: 35894511 pmcid: 9377782 doi: 10.1152/jn.00255.2022
Steinmetz, A. et al. The Greifswald Post COVID Rehabilitation Study and Research (PoCoRe)–Study Design, Characteristics and Evaluation Tools. J. Clin. Med. 12, 624 (2023).
pubmed: 36675551 pmcid: 9861069 doi: 10.3390/jcm12020624
OECD. Investing in health systems to protect society and boost the economy: Priority investments and order-of-magnitude cost estimates (abridged version). OECD Policy Responses to Coronavirus (COVID-19) https://www.oecd.org/coronavirus/policy-responses/investing-in-health-systems-to-protect-society-and-boost-the-economy-priority-investments-and-order-of-magnitude-cost-estimates-abridged-version-94ba313a/ (2022).
Stanley, H. B. & Bensafi, M. A data set of symptoms and needs of individuals affected by COVID-19. Nat. Sci. Data 11, 122 (2024).
Bussiere, N. et al. Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up. Chem. Senses 47, bjac010 (2022).
pubmed: 35522081 doi: 10.1093/chemse/bjac010
Doty, R. L. Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health. Trends Mol. Med. 28, 781–794 (2022).
pubmed: 35810128 pmcid: 9212891 doi: 10.1016/j.molmed.2022.06.005
Boscolo-Rizzo, P. et al. High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. Rhinology 59, 517–527 (2021).
pubmed: 34553706
Watson, D. L. B. et al. Altered smell and taste: Anosmia, parosmia and the impact of long Covid-19. PLoS One 16, e0256998 (2021).
doi: 10.1371/journal.pone.0256998
Connelly, D. ‘My whole world changed’: The repulsive smells that linger for months post COVID. Pharmaceutical J. 308, No. 7960 (2022)
Tan, N. K. W. et al. The burden of prolonged smell and taste loss in covid-19. BMJ 378, o1895 (2022).
pubmed: 35896196 doi: 10.1136/bmj.o1895
Barrea, L. et al. Dietary Recommendations for Post-COVID-19 Syndrome. Nutrients 14, https://doi.org/10.3390/nu14061305 (2022).
Ferrulli, A., Senesi, P., Terruzzi, I. & Luzi, L. Eating Habits and Body Weight Changes Induced by Variation in Smell and Taste in Patients with Previous SARS-CoV-2 Infection. Nutrients 14, 5068 (2022).
pubmed: 36501098 pmcid: 9738767 doi: 10.3390/nu14235068
Bernard Stoecklin, S. et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro. Surveill. 25, 2000094 (2020).
pubmed: 32070465 pmcid: 7029452 doi: 10.2807/1560-7917.ES.2020.25.6.2000094
Eurostat. Daily smokers of cigarettes by sex, age and educational attainment level. https://ec.europa.eu/eurostat/databrowser/view/HLTH_EHIS_SK3E__custom_6000386/default/table?lang=en&page=time:2019 (2019).
Fox, J. & Weisberg, S. Companion to Applied Regression 3rd edn (Sage, 2020).
The_jamovi_project. jamovi version 2.2.5 [computer software]. https://www.jamovi.org (2021).
Newcombe, R. & Altman, D. in Statistics with Confidence Ch. 6 (BMJ Books, 2017).
Lin, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69, 997–1001 (2020).
pubmed: 32241899 doi: 10.1136/gutjnl-2020-321013
Cagnazzo, F. et al. Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature. J. Neurol. 268, 2656–2665 (2021).
pubmed: 33125542 doi: 10.1007/s00415-020-10285-9
Caruso, D. et al. Post-acute sequelae of COVID-19 pneumonia: Six-month chest CT follow-up. Radiology 301, E36–E405 (2021).
doi: 10.1148/radiol.2021210834
Struyf, T. et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst. Rev. 2022, CD013665 (2022).
Vaira, L. A. et al. COVID-19 related persistent olfactory disorders represent an unprecedented challenge. Am. J. Otolaryngol. 44, 103667 (2023).
pubmed: 36270236 doi: 10.1016/j.amjoto.2022.103667
Cooper, K. W. et al. COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. Neuron 107, 219–233 (2020).
pubmed: 32640192 pmcid: 7328585 doi: 10.1016/j.neuron.2020.06.032
Zhao, Y.-H., Zhao, L., Yang, X.-C. & Wang, P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and meta-analysis. Rev. Cardiovasc. Med. 22, 159–165 (2021).
pubmed: 33792257 doi: 10.31083/j.rcm.2021.01.238
Menni, C. et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 399, 1618–1624 (2022).
pubmed: 35397851 pmcid: 8989396 doi: 10.1016/S0140-6736(22)00327-0
Kalish, H. et al. Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. Sci. Transl. Med. 13, eabh3826 (2021).
pubmed: 34158410 pmcid: 8432952 doi: 10.1126/scitranslmed.abh3826
Vihta, K. D. et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciac613 (2022).
Byambasuren, O. et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. J. Assoc. Med. Microbiol. Infectious Dis. Can. 5, 223–234 (2020).
Tande, A. J. et al. Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening. Clin. Infect. Dis. 74, 59–65 (2022).
pubmed: 33704435 doi: 10.1093/cid/ciab229
Stankevice, D., Fjaeldstad, A. W., Agergaard, J. & Ovesen, T. Long-Term COVID-19 Smell and Taste Disorders Differ Significantly from Other Post-Infectious Cases. Laryngoscope 133, 169–174 (2023).
pubmed: 36305529 doi: 10.1002/lary.30453
Makaronidis, J. et al. Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in peopl. BMC Infect. Dis. 21, 221 (2021).
pubmed: 33632171 pmcid: 7905973 doi: 10.1186/s12879-021-05927-w
Kaye, R., Chang, C. W. D., Kazahaya, K., Brereton, J. & Denneny, J. C. COVID-19 Anosmia Reporting Tool: Initial Findings. Otolaryngol. Head Neck Surg. 163, 132–134 (2020).
pubmed: 32340555 doi: 10.1177/0194599820922992
Lechien, J. R. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Oto Rhino Laryngol. 277, 2251–2261 (2020).
doi: 10.1007/s00405-020-05965-1
Groff, A. et al. Gastrointestinal Manifestations of COVID-19: A Review of What We Know. Ochsner. J. 21, 177–180 (2021).
pubmed: 34239378 pmcid: 8238098 doi: 10.31486/toj.20.0086
Jason, L. A. et al. COVID-19 symptoms over time: comparing long-haulers to ME/CFS. Fatigue 9, 59–68 (2021).
pubmed: 34484973 pmcid: 8411893
Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-022-00846-2 (2023)
Polly, S. & Fernandez, A. P. Common skin signs of COVID-19 in adults: An update. Cleve Clin. J. Med. 89, 161–167 (2022).
pubmed: 35232829 doi: 10.3949/ccjm.89a.21126
Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021).
pubmed: 34308300 pmcid: 8280690 doi: 10.1016/j.eclinm.2021.101019
Apple, A. C. et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann. Clin. Transl. Neurol. 9, 221–226 (2022).
pubmed: 35043593 pmcid: 8862406 doi: 10.1002/acn3.51498
Croy, I., Nordin, S. & Hummel, T. Olfactory Disorders and Quality of Life—An Updated Review. Chem. Senses 39, 185–194 (2014).
pubmed: 24429163 doi: 10.1093/chemse/bjt072
Keller, A. & Malaspina, D. Hidden consequences of olfactory dysfunction: a patient report series. BMC Ear. Nose Throat Disord. 13, 8 (2013).
pubmed: 23875929 pmcid: 3733708 doi: 10.1186/1472-6815-13-8
Manesse, C. et al. Dysosmia-Associated Changes in Eating Behavior. Chemosens. Percept. 10, 104–113 (2017).
doi: 10.1007/s12078-017-9237-3
Manesse, C. et al. The prevalence of olfactory deficits and their effects on eating behavior from childhood to old age: A large-scale study in the French population. Food Qual. Prefer. 93, 104273 (2021).
Ferdenzi, C. et al. Recovery From COVID-19-Related Olfactory Disorders and Quality of Life: Insights From an Observational Online Study. Chem. Senses 46, bjab028 (2021).
pubmed: 34097726 doi: 10.1093/chemse/bjab028
Bousquet, C., Bouchoucha, K., Bensafi, M. & Ferdenzi, C. Phantom smells: a prevalent COVID-19 symptom that progressively sets in. Eur. Arch. Otorhinolaryngol 280, 1219–1229 (2023).
pubmed: 36173444 doi: 10.1007/s00405-022-07649-4
Lassale, C. et al. Healthy dietary indices and risk of depressive outcomes: asystematic review and meta-analysis of observational studies. Mol. Psychiatry 24, 965–986 (2019).
pubmed: 30254236 doi: 10.1038/s41380-018-0237-8
Salari-Moghaddam, A., Saneei, P., Larijani, B. & Esmaillzadeh, A. Glycemic index, glycemic load, and depression: a systematic review and meta-analysis. Eur. J. Clin. Nutr. 73, 356–365 (2019).
pubmed: 30054563 doi: 10.1038/s41430-018-0258-z
Kaiser, A., Schaefer, S. M., Behrendt, I., Eichner, G. & Fasshauer, M. Association of sugar intake from different sources with incident depression in the prospective cohort of UK Biobank participants. Eur. J. Nutr. https://doi.org/10.1007/s00394-022-03022-7 (2022).
Yom-Tov, E., Lekkas, D. & Jacobson, N. C. Association of COVID19-induced anosmia and ageusia with depression and suicidal ideation. J. Affect. Disord. Rep. 5, 100156 (2021).
pubmed: 34075369 pmcid: 8154197 doi: 10.1016/j.jadr.2021.100156
Croy, I. & Hummel, T. Olfaction as a marker for depression. J. Neurol. 264, 631–638 (2017).
pubmed: 27393116 doi: 10.1007/s00415-016-8227-8
Mahmut, M. K. & Croy, I. The role of body odors and olfactory ability in the initiation, maintenance and breakdown of romantic relationships—A review. Physiol. Behav. 207, 179–184 (2019).
pubmed: 31077678 doi: 10.1016/j.physbeh.2019.05.003
Lübke, K. T. & Pause, B. M. Always follow your nose: The functional significance of social chemosignals in human reproduction and survival. Horm. Behav. 68, 134–144 (2015).
pubmed: 25637403 doi: 10.1016/j.yhbeh.2014.10.001
Otte, M. S. et al. Impact of COVID-19-Mediated Olfactory Loss on Quality of Life. ORL J. Otorhinolaryngol. Relat. Spec. 85, 1–6 (2023).
pubmed: 35413715 doi: 10.1159/000523893
OECD. State of Health in the EU: Country Health Profiles France: Country Health Profile 2021. https://read.oecd-ilibrary.org/social-issues-migration-health/france-country-health-profile-2021_7d668926-en#page1 (2021).
Besser, G., Liu, D. T., Renner, B., Hummel, T. & Mueller, C. A. Olfactory implant: Demand for a future treatment option in patients with olfactory dysfunction. Laryngoscope 129, 312–316 (2019).
pubmed: 30145818 doi: 10.1002/lary.27476
Pinger, M. et al. Perceived utility of electronic noses in patients with loss of smell. Eur. Arch. Oto Rhino Laryngol. 278, 2155–2156 (2021).
doi: 10.1007/s00405-021-06708-6
Sheeran, P., Webb, T. L. & Gollwitzer, P. M. The Interplay Between Goal Intentions and Implementation Intentions. Pers. Soc. Psychol. Bull. 31, 87–98 (2005).
pubmed: 15574664 doi: 10.1177/0146167204271308
Bohns, V. K. & Flynn, F. J. “Why didn’t you just ask?” Underestimating the discomfort of help-seeking. J Exp. Soc. Psychol. 46, 402–409 (2010).
doi: 10.1016/j.jesp.2009.12.015
Schnell, R., Noack, M. & Torregroza, S. Differences in general health of internet users and non-users and implications for the use of web surveys. Surv. Res. Methods 11, 105–123 (2017).
Deems, D. A. et al. Smell and Taste Disorders, A Study of 750 Patients From the University of Pennsylvania Smell and Taste Center. Arch. Otolaryngol. Head Neck Surg. 117, 519–528 (1991).
pubmed: 2021470 doi: 10.1001/archotol.1991.01870170065015
Doty, R. L. Measurement of chemosensory function. World J. Otorhinolaryngol. Head Neck. Surg. 4, 11–28 (2018).
pubmed: 30035257 pmcid: 6051764 doi: 10.1016/j.wjorl.2018.03.001
Ohla, K. et al. A follow-up on quantitative and qualitative olfactory dysfunction and other symptoms in patients recovering from COVID-19 smell loss. Rhinol. J. 60, 207–217 (2022).
Fernández-de-las-Peñas, C. et al. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J. Clin. Med. 11, https://doi.org/10.3390/jcm11020413 (2022).
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
pubmed: 32087114 pmcid: 7159018 doi: 10.1016/S1473-3099(20)30120-1
de Bellefon, M.-P. (PSAR A. territoriale-I., Eusebio, P. ((PSAR A. territoriale-I., Forest, J. ((PSAR A. territoriale-I. & Warnod, R. ((PSAR A. territoriale-I. 38% de la population française vit dans une commune densément peuplée. Statistiques et études https://www.insee.fr/fr/statistiques/4252859 (2019).
INSEE. Population statistics of France. https://www.insee.fr/fr/statistiques/1893198 (2022).
Bensafi, M. & Stanley, H. B. COVID-19—Symptoms—Impact on quality of life and needs of affected people. Zenodo https://doi.org/10.5281/zenodo.7920303 (2023).
Stanley, H. B. & Bensafi, M. A data set of symptoms and needs of individuals affected by COVID-19. Sci Data 11, 122 (2024).
pubmed: 38267450 pmcid: 10808179 doi: 10.1038/s41597-024-02961-6

Auteurs

Halina B Stanley (HB)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France. halina.stanley@cnrs.fr.

Veronica Pereda-Campos (V)

Équipe de Médecine Evolutive Faculté de chirurgie dentaire-UMR5288, CNRS/Université Paul-Sabatier Toulouse III, Toulouse, 31400, France.

Marylou Mantel (M)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France.
Équipe de Médecine Evolutive Faculté de chirurgie dentaire-UMR5288, CNRS/Université Paul-Sabatier Toulouse III, Toulouse, 31400, France.

Catherine Rouby (C)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France.

Christelle Daudé (C)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France.

Pierre-Emmanuel Aguera (PE)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France.

Lesly Fornoni (L)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France.

Thomas Hummel (T)

Smell & Taste Clinic, Department of Otorhinlaryngology, Technische Universität Dresden, Dresden, Germany.

Susanne Weise (S)

Smell & Taste Clinic, Department of Otorhinlaryngology, Technische Universität Dresden, Dresden, Germany.

Coralie Mignot (C)

Smell & Taste Clinic, Department of Otorhinlaryngology, Technische Universität Dresden, Dresden, Germany.

Iordanis Konstantinidis (I)

2nd Academic ORL Department, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece.

Konstantinos Garefis (K)

2nd Academic ORL Department, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece.

Camille Ferdenzi (C)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France.

Denis Pierron (D)

Équipe de Médecine Evolutive Faculté de chirurgie dentaire-UMR5288, CNRS/Université Paul-Sabatier Toulouse III, Toulouse, 31400, France.

Moustafa Bensafi (M)

Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, NEUROPOP, F-69500, Bron, France. moustafa.bensafi@cnrs.fr.

Classifications MeSH